Toboroz
A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
NCT07876557· 2. fázis· Shanghai Junshi Bioscience Co., Ltd.· Forrás
Toboroz
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· 3. fázis· Antengene Biologics Limited· Forrás
Toboroz
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
NCT07653685· 1/2. fázis· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Forrás
Még nem toboroz
Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer
NCT07795424· 2. fázis· Shengjing Hospital· Forrás
Toboroz
A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
NCT07739758· 3. fázis· MediLink Therapeutics (Suzhou) Co., Ltd.· Forrás
Toboroz
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
NCT07700667· 2. fázis· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Forrás
Toboroz
SMP-656 for HER2-Positive Advanced Breast Cancer
NCT07726342· 2. fázis· Chengdu SciMount Pharmatech Co., Ltd.· Forrás
Toboroz
Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
NCT07586124· 2. fázis· Lepu Biopharma Co., Ltd.· Forrás
Toboroz
Two-component Radiology-guided Autonomous Cascade Engine (TRACE)
NCT07651644· Liaoning Cancer Hospital & Institute· Forrás
Fut, nem toboroz
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer
NCT07791602· 2. fázis· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Forrás
Toboroz
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587· 1. fázis· Shanghai Henlius Biotech· Forrás
Toboroz
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
NCT07474727· 2. fázis· Multitude Therapeutics Inc.· Forrás
Toboroz
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703· 3. fázis· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Forrás
Toboroz
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
NCT06951646· 2. fázis· Second Xiangya Hospital of Central South University· Forrás
Még nem toboroz
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
NCT07483684· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Forrás
Még nem toboroz
A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study
NCT07375979· Shanghai Pulmonary Hospital, Shanghai, China· Forrás
Toboroz
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT07347600· Hoffmann-La Roche· Forrás
Toboroz
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
NCT07284134· 3. fázis· Shanghai Junshi Bioscience Co., Ltd.· Forrás
Toboroz
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· 3. fázis· ArriVent BioPharma, Inc.· Forrás
Toboroz
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
NCT07182682· 3. fázis· Dizal (Jiangsu) Pharmaceutical Co., Ltd.· Forrás
Toboroz
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT07176650· 1. fázis· Shanghai Henlius Biotech· Forrás
Toboroz
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
NCT07160335· 1. fázis· Shanghai Henlius Biotech· Forrás
Toboroz
JS207 Combination Therapy in Triple-negative Breast Cancer
NCT07045311· 2. fázis· Shanghai Junshi Bioscience Co., Ltd.· Forrás
Toboroz
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT07169994· 1/2. fázis· MediLink Therapeutics (Suzhou) Co., Ltd.· Forrás
Toboroz
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
NCT07122687· 2. fázis· Innovent Biologics (Suzhou) Co. Ltd.· Forrás
Toboroz
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
NCT07047365· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Forrás
Toboroz
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
NCT07008976· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Forrás
Toboroz
Optimal Application Timing of ADC Drugs for Advanced Breast Cancer
NCT07657130· 2. fázis· Liaoning Cancer Hospital & Institute· Forrás
Toboroz
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· 3. fázis· BeOne Medicines· Forrás
Toboroz
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996· 3. fázis· BeOne Medicines· Forrás
Toboroz
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552· 1. fázis· NextCure, Inc.· Forrás
Toboroz
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
NCT06839105· 1. fázis· Shanghai Junshi Bioscience Co., Ltd.· Forrás
Toboroz
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
NCT06680921· 3. fázis· Jiangsu Simcere Pharmaceutical Co., Ltd.· Forrás
Toboroz
A Phase 2 Clinical Study of ABSK061 and ABSK043
NCT06632262· 2. fázis· Abbisko Therapeutics Co, Ltd· Forrás
Toboroz
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
NCT06637163· 2. fázis· Shanghai Zhongshan Hospital· Forrás
Toboroz
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
NCT06416410· 3. fázis· Allist Pharmaceuticals, Inc.· Forrás
Toboroz
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery
NCT06109454· Liaoning Cancer Hospital & Institute· Forrás
Toboroz
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
NCT06758557· 1/2. fázis· Huabo Biopharm Co., Ltd.· Forrás
Toboroz
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776· Daiichi Sankyo· Forrás
Toboroz
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
NCT06155396· 2. fázis· RemeGen Co., Ltd.· Forrás
Toboroz
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
NCT06155084· 1/2. fázis· Hinova Pharmaceuticals Inc.· Forrás
Toboroz
Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )
NCT06249308· Fudan University· Forrás
Toboroz
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686· 2. fázis· MediLink Therapeutics (Suzhou) Co., Ltd.· Forrás
Showing 50 of 91.